相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1
Eric S. Daar et al.
ANNALS OF INTERNAL MEDICINE (2011)
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
Christoph Wyen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
Heather J. Ribaudo et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
Florencia Pereyra et al.
SCIENCE (2010)
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
Awewura Kwara et al.
AIDS (2009)
Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals
M. Arab-Alameddine et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy
Paul E. Sax et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
Julia di Iulio et al.
PHARMACOGENETICS AND GENOMICS (2009)
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
Christoph Wyen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Aberrant splicing caused by single nucleotide polymorphism c.516G> T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver
Marco H. Hofmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7
Margalida Rotger et al.
PHARMACOGENETICS AND GENOMICS (2007)
PLINK: A tool set for whole-genome association and population-based linkage analyses
Shaun Purcell et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals
M. Rotger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Population structure and eigenanalysis
Nick Patterson et al.
PLOS GENETICS (2006)
Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues
Danxin Wang et al.
PHARMACOGENETICS AND GENOMICS (2006)
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection - A randomized controlled trial
Roy M. Gulick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Principal components analysis corrects for stratification in genome-wide association studies
Alkes L. Price et al.
NATURE GENETICS (2006)
Genetic variability of CYP2B6 in populations of African and Asian origin:: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz
K Klein et al.
PHARMACOGENETICS AND GENOMICS (2005)
Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir:: An adult AIDS clinical trials group study
DW Haas et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals
DB Clifford et al.
ANNALS OF INTERNAL MEDICINE (2005)
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects
S Rodriguez-Novoa et al.
CLINICAL INFECTIOUS DISEASES (2005)
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens
K Tsuchiya et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians:: Demonstration of phenotypic null alleles
T Lang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
GK Robbins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection
RW Shafer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128
DW Haas et al.
HIV CLINICAL TRIALS (2003)
The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
BA Ward et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus
EP Acosta et al.
CLINICAL INFECTIOUS DISEASES (2003)
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS clinical trial group study 398
M Pfister et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Hepatic CYP2B6 expression: Gender and ethnic differences and relationship to CYP2B6 genotype and CAR (Constitutive Androstane Receptor) expression
V Lamba et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
分享论文
